Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Background/Purpose: Microvascular injury is one of the first pathological events in systemic sclerosis, and precedes the fibrosis. A consequence of vascular damage is the exposure of subendothelial connective tissue that causes activation of platelets and local serotonin (5-hydroxytryptamine, 5-HT) release. Binding of 5-HT to 5-HT2B receptors on fibroblasts results in increased myofibroblast differentiation and release of excessive amounts of matrix proteins subsequently leading to fibrosis. Thus, pharmacologic inhibition of 5-HT2B receptors may represent a new treatment opportunity for systemic sclerosis. In this study a novel highly selective 5-HT2B receptor antagonist was evaluated for its ability to reduce the production of matrix proteins in human dermal fibroblasts and to ameliorate fibrosis in the tight-skin-1 model of systemic sclerosis.
Methods: Dermal fibroblasts isolated from patients with systemic sclerosis were cultured with different concentrations of the 5-HT2B receptor antagonist AM1125 with or without 1 µM 5-HT. Anti-fibrotic effects were evaluated by measuring matrix production, myofibroblast differentiation and TGF-β production. The tight-skin-1 model was used to evaluate anti-fibrotic effects in vivo using a therapeutic treatment approach. AM1125 was administered at 10 and 50 mg/kg orally, b.i.d. from week 5 to week 10. Hypodermal thickening, myofibroblast counts and collagen production (hydroxyproline) were evaluated at the end of the treatment period.
Results: In vitro AM1125 dose-dependently reduced TGF-β, PAI, nuclear SMAD2/3 and collagens in human dermal fibroblasts. In addition, stress fiber formation and α-SMA mRNA were reduced indicating decreased myofibroblast differentiation. Therapeutic treatment with the 5-HT2B receptor antagonist AM1125 at 50 mg/kg reduced hypodermal thickness (p<0.001), myofibroblast counts (p<0.05) and hydroxyproline content (p<0.01) in the tight-skin-1 model. In addition, the lower dose (10 mg/kg) reduced hypodermal thickness (p<0.001).
Conclusion: The results demonstrate that the 5-HT2B receptor antagonist AM1125 prevents pro-fibrotic events in human dermal fibroblasts and attenuates dermal fibrosis using a therapeutic treatment approach in the tight-skin-1 model. Thus, 5-HT2B receptor antagonists, exemplified by the novel compound AM1125, could represent a new treatment opportunity for systemic sclerosis.
To cite this abstract in AMA style:Wenglén C, Pettersson L, Arozenius H, Ekström G. A Novel Highly Selective 5-Hydroxytryptamine 2B (5-HT2B) Receptor Antagonist Ameliorating Fibrosis in Preclinical Models of Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-novel-highly-selective-5-hydroxytryptamine-2b-5-ht2b-receptor-antagonist-ameliorating-fibrosis-in-preclinical-models-of-systemic-sclerosis/. Accessed May 31, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-highly-selective-5-hydroxytryptamine-2b-5-ht2b-receptor-antagonist-ameliorating-fibrosis-in-preclinical-models-of-systemic-sclerosis/